ECOG-ACRIN Cancer Research Group

You may be eligible to participate in a #PancreaticCancer study, EA2192/APOLLO, for patients with #PancreaticCancer that has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation. Learn more: bit.ly/apollo-trial #pancsm

Anthony Letai, MD, PhD

Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration.

Learn more: bit.ly/4pRWiZy

We congratulate Dr. Anthony Letai on his appointment as NCI Director. His deep scientific expertise & reputation as a collaborative leader make him an excellent choice to drive progress against #cancer. We look forward to working with him! #CancerResearch #ClinicalTrials

Today is #WorldCancerResearchDay! Catch up on the latest
@eaonc.bsky.social research highlights from our August newsletter here ➡️https://bit.ly/aug25research #EAOnc #CancerResearch

Today is the 2025 Rally for Medical Research! #RallyForNIH unites patients, survivors, researchers & advocates urging Congress to make National Institutes of Health funding a national priority.

Join us in calling for sustained, robust NIH support. Important info➡️ rallyformedicalresearch.org

Home - Rally for Medical Research Join advocates from around the country for the 2025 Rally for Medical Research! The Hill Day will take place on Thursday, September 18, with advocates ... Read moreHome

#NIH research is the basis for countless treatments and cures for patients battling life-threatening and chronic conditions. Join today’s #RallyMedRes & urge Congress to support robust, sustained funding for NIH. Tools & resources here: rallyformedicalresearch.org #FundNIH

ICYMI: Check out our round-up of recently published
@eaonc.bsky.social research results. More here ➡️ bit.ly/aug25research #EAOnc

September is #ProstateCancerAwarenessMonth 💙. This month, we’re spotlighting EA8191/INDICATE, a #ClinicalTrial treating #ProstateCancer that has come back after surgery with apalutamide and targeted radiation based on PET imaging. More here: bit.ly/indicate-trial

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M House joins Senate in rejecting Trump’s proposed 40% NIH cuts - The Cancer Letter The House is on track to join the Senate in rejecting the Trump administration’s budget proposal that would cut NIH by $18 billion. To access this subscriber-only content please log in or subscribe.If...

More good news from Washington: Last week the House Labor-HHS Subcommittee advanced its FY26 spending bill, increasing both NCI & NIH funding and rejecting the proposed cuts. Thank you for working to prioritize #CancerResearch, patients, and survivors. Read more: bit.ly/4n3sYNN

In our August newsletter, the co-chairs spotlight an open letter to Congress from the National Clinical Trials Network Cooperative Group Chairs, detailing its significant contributions to patient welfare. Read their editorial and the full letter here: bit.ly/41x0VO5 #CancerResearch #ClinicalTrials

The EA3211 clinical study is testing a potential new treatment for patients with #HeadAndNeckCancer that has spread to a limited number of places. Learn more: bit.ly/ea3211-study #hncsm

Submit an Abstract for the 2025 Young Investigator Symposium by Thursday, 9/11! 🩻

We are now accepting research abstracts from early-career investigators interested in presenting your research as part of the upcoming Fall 2025 Group Meeting. More: bit.ly/yis-fall25 #EAOnc

Trial Activation: EA2234/STOPGAP II, led by Dr. Maheswari Senthil of UCI Health, is a randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis. More: bit.ly/ea2234-stopg... #StomachCancer

Trial Activation: EAA241, led by Dr. Amany Keruakous of @wellstarhealth.bsky.social, is a randomized phase II trial comparing daratumumab-bortezomib-dexamethasone vs cyclophosphamide-bortezomib dexamethasone in newly diagnosed #MultipleMyeloma. For more info: bit.ly/EAA241

ICYMI: Check out our round-up of recently published @eaonc.bsky.social and @precogonc.bsky.social research results. More here ➡️ bit.ly/july25research

#ClinicalTrials #BreastCancer #CancerControl #CancerSurvivorship #HeadandNeck #LungCancer #Melanoma

An encouraging update from Washington re: support for #CancerResearch funding! Good news for the entire cancer research community--but most importantly for patients.

#FindingsFriday: Did you know we publish patient-friendly, 1-2 page summaries of the results of many of our #ClinicalTrials? View them here: bit.ly/trial-summar... #CancerResearch #ClinicalTrials

Trial Spotlight: Ken Cardona Gives an Update on the EA7211/STRASS 2 Sarcoma Trial In Sarcoma Cancer Awareness Month, we highlight a clinical trial for patients with this rare cancer, which has had few treatment advances

#RareCancers like #sarcoma can be difficult to study--but cooperative research groups like ours make it possible. This #SarcomaAwarenessMonth, learn about EA7211/STRASS 2, an international trial in #RetroperitonealSarcoma: bit.ly/EA7211STRASS... @eortc.org

Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer

Great work to Atlantic Health System for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM

Do you have an aggressive B-cell #Lymphoma that has either come back or persisted after initial therapy? If so, you may be eligible to participate in #ClinicalTrial EA4231. More info here: bit.ly/EA4231 #lymsm

Read more from our co-chairs on the importance of protecting public support for biomedical research: bit.ly/3IvxNQD #CancerResearch #ClinicalTrials

Today is #GBMDay! 🧠 Learn about EAF223/GABLE, a #Glioblastoma study testing different imaging techniques that could help make better predictions about #BrainCancer progression. Learn more here: bit.ly/gable-trial

Did you know July is #SarcomaAwarenessMonth? Take a moment to read our trial spotlight on EA7211/STRASS 2. This #clinicaltrial is the second randomized study ever performed in retroperitoneal soft tissue #sarcoma. More: bit.ly/EA7211STRASS...

Now Enrolling: EA5231/CLEAR Study for Patients With Operable Non-Small Cell Lung Cancer This clinical trial aims to improve survival for high-risk patients by adding a targeted therapy to standard post-surgery immunotherapy

Now Enrolling: CLEAR Study for Operable Non-Small Cell Lung Cancer blog-ecog-acrin.org/now-enrollin...

In #ClinicalTrial EA7222, investigators are testing doxorubicin plus pembrolizumab vs. doxorubicin alone for patients with advanced undifferentiated pleomorphic sarcoma (UPS). For more information: bit.ly/EA7222 #sarcomaawareness

Congratulations to Dr. Petros Grivas on receiving the 2025 Young Investigator Award from @eaonc.bsky.social! He's recognized for a distinguished record of innovative research, outstanding clinical practice, and unwavering dedication to advancing the field of genitourinary oncology.

In the latest edition of our advocacy blog, Glenn Sykes, #KidneyCancer survivor and #CancerResearch advocate, writes about the importance of a strong patient-oncologist bond. In honor of #NationalCancerSurvivorsMonth, read more: bit.ly/44Vobb4

Grivas, Schiller, Avigan receive ECOG-ACRIN 2025 scientific leadership, mentorship awards - The Cancer Letter Petros Grivas, Joan Schiller, and Zachary Avigan were named recipients of the ECOG-ACRIN Cancer Research Group annual scientific awards, which are funded by the ECOG Research & Education Foundation. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not […]

Petros Grivas of @fredhutch.bsky.social, Joan Schiller of @ouchinternational.bsky.social, and Zachary Avigan receive ECOG-ACRIN (‪@eaonc.bsky.social‬) 2025 scientific leadership, mentorship awards
https://cancerletter.com/in-brief/20250613_8b/

Institution Spotlight: Stanford Cancer Institute The Stanford Cancer Institute was founded in 2004 and builds on Stanford’s long history of cancer research, which started in 1956 when Henry Kaplan developed the linear accelerator. The institute is…

The Stanford Cancer Institute has been an @eaonc.bsky.social Cancer Research Group Main Member Institution since 1985. This membership reflects our leadership in national cancer research, helping shape and conduct NCI-sponsored clinical trials nationwide.  blog-ecog-acrin.org/institution-...

A phase II trial led by Dr. Barbara Burtness studying results of transoral surgery + risk-based adjuvant treatment in #HPV related #oropharyngealcancer showed surgery w/tailored postop treatment led to excellent outcomes.
ascopubs.org/doi/10.1200/...
@eaonc.bsky.social @yaleschoolofmed.bsky.social